For research use only. Not for therapeutic Use.
Potent LSD1 inhibitor in vitro and selective versus monoamine oxidases A/B and the LSD1 homologue, LSD2 with Ki(inact) values 0.059 μM, 2.6 μM, 6.5 μM, and ca 11 μM for LSD1, MAO-A, MAO-B, and LSD2 respectively. Bizine was found to be effective at modulating bulk histone methylation in cancer cells. Moreover, neurons exposed to oxidative stress were protected by the presence of bizine, suggesting potential applications in neurodegenerative disease.
| Catalog Number | I047605 |
| CAS Number | 2108826-15-7 |
| Molecular Formula | C18H23N3O.HCl |
| Purity | ≥95% |
| IUPAC Name | N-[4-(2-hydrazinylethyl)phenyl]-4-phenylbutanamide;hydrochloride |
| InChI | InChI=1S/C18H23N3O.ClH/c19-20-14-13-16-9-11-17(12-10-16)21-18(22)8-4-7-15-5-2-1-3-6-15;/h1-3,5-6,9-12,20H,4,7-8,13-14,19H2,(H,21,22);1H |
| SMILES | C1=CC=C(C=C1)CCCC(=O)NC2=CC=C(C=C2)CCNN.Cl |
| Reference | P. Prusevich et al. A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chem. Biol. 2014, 9, 1284-1293. |
